
A blockbuster breast cancer niche has Roche and Sanofi in the lead
As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.
As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.